• 购宝钱包APP

    购宝钱包APP /科研细胞 /人源细胞系 /血液 /Molt-4(人急性淋巴母细胞白血病细胞)

    Molt-4(人急性淋巴母细胞白血病细胞)

    CBP60525

    询 价
    MOLT4细胞全景
    产品描述
    产品数据库
    I. General information 
    Synonyms: Molt-4
    Background: MOLT-4 was derived from the same patient as the MOLT-3 cell line (ATCC CRL-1552). The line was established from cells taken from a patient in relapse.
    Species: Homo sapiens, human
    Tissue: Blood
    Disease: acute lymphoblastic leukemia
    Gender: male,19 years 
    Morphology: lymphoblast
    Growth Mode: suspension
    DNA Profile: Amelogenin: XY
    CSF1PO: 11, 12, 13
    D13S317: 12, 13
    D16S539: 11, 14
    D5S818: 12
    D7S820: 8, 10, 11
    THO1: 6, 8
    TPOX: 8
    vWA: 17, 18
    Our Cell Line Authentication Service
    Culture Medium:

    RPMI1640+10%FBS

    Molt-4完全培养基,# CBP60525M
    We strongly suggest to purchase the complete medium from us.

    Cryopreservation medium: 90%FBS+10%DMSO
    Antigen Expression: CD1 (49%), CD2 (35%), CD3 A (26%) B (33%) C (34%), CD4 (55%), CD5 (72%), CD6 (22%), CD7 (77%)
    Genes Expressed: high levels of terminal deoxynucleotidyl transferase (TdT) are produced.
    Cellular Products: high levels of terminal deoxynucleotidyl transferase (TdT) are produced
    Tumor Formation: Yes, in untreated nude mice, anti lymphocyte serum treated mice and X-irradiated mice,Ref
    Comments: The patient had received prior multidrug chemotherapy. There is a G -> A mutation at codon 248 of the p53 gene.
    P53 is not expressed.
    The cells do not produce immunoglobulin or Epstein-Barr virus. The line was originally contaminated with mycoplasma but has been cured with antibiotics.
    For more information, please contact us (4008-750-250).

    客服

    微信

    扫一扫,添加二维码

    电话

    留言

    药靶模型联系方式: 华东销售经理(上海):18240630236/18114809104 华东销售经理(江苏、安徽):15715191010 华北销售经理:18628311252 华南销售经理:13823536064 华中&华西销售经理:18071545918 全国销售经理:13816461235
    诊断标准品联系方式: 华东销售经理:15000320447 华北销售经理:18628311252 华南销售经理:13823536064 华中&华西销售经理:18071545918 全国销售经理:13816461235

    扫二维码

    立即提交